|
| founded = 1992 | founder = Leonard Bell | location_city = Cheshire, Connecticut, U.S. | key_people = Max E. Link (Chairman) David L. Hallal(CEO) | industry = Pharmaceutical | products = Soliris | revenue = US$ 1151.346 million (2013) 37%〔(【引用サイトリンク】title=Alexion Pharmaceuticals 2013 Annual Report )〕 | operating_income = US$ 528.010 mil (2013)31%〔 | net_income = US$ 252.895 mil (2013)〔 | assets = US$ 3.317696 bil (2013)27%〔 | equity = US$ 2.382079 bil (2013)21%〔 | num_employees = 1774 (December 2013)〔 | homepage = }} Alexion Pharmaceuticals Inc. is an American pharmaceutical company best known for its development of Soliris, a drug used to treat the rare disorders atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH).〔(【引用サイトリンク】title=Alexion Submits Application for Soliris )〕〔(【引用サイトリンク】title=Alexion Pharmaceuticals on the Forbes World’s Most Innovative Companies List )〕 The company is also involved in immune system research related to autoimmune diseases. It employs about 2,400 people worldwide. ==History== Alexion Pharmaceuticals was founded in 1992 at Science park in New Haven, Connecticut by Leonard Bell.〔 Bell would serve as the company's CEO until 2015.〔 In 2000, Alexion moved its headquarters from New Haven to Cheshire, Connecticut. Since 2006, Alexion has been a supporter of Healthcare Research and Quality studies at Duke University for aspirin and Clopidogrel (trade name Plavix).〔(【引用サイトリンク】title= More Support for Long-Term Plavix to Improve Stent Safety )〕 Alexion received US Food and Drug Administration (FDA) approval for Soliris in 2007. It was initially approved to treat paroxysmal nocturnal hemoglobinuria, a rare blood disorder.〔 In 2010, there was an outbreak of hemolytic-uremic syndrome caused by Enterohaemorrhagic Escherichia coli (EHEC) in Germany. Soliris was considered as a treatment option due to its effectiveness in treating Atypical hemolytic uremic syndrome, an illness similar to the one caused by the EHEC infection. As a result, Alexion's German subsidiary provided an unspecified number of Soliris doses at no charge to physicians who requested it.〔(【引用サイトリンク】title=Alexion treating Europe's E coli victims )〕 On April 4, 2011, Alexion was added to the NASDAQ-100, a group composed of the 100 largest non-financial stocks traded on the Nasdaq; with a market value of USD 8.5 billion it replaced Genzyme Corporation.〔(【引用サイトリンク】title=Alexion Pharmaceuticals, Inc. to Join the NASDAQ-100 Index Beginning April 4, 2011 )〕 On April 1, 2015, Bell was replaced as CEO by David Hallal.〔 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Alexion Pharmaceuticals」の詳細全文を読む スポンサード リンク
|